Company to host breakfast symposium presentation on radiation safety in the cath lab and robotic precision
Waltham, MA – September 11, 2014 – Corindus Vascular Robotics, Inc. [OTCQB: CVRS], a leading developer of precision vascular robotics, will showcase its CorPath©Vascular Robotic System during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2014 meeting, September 13 – 17 in Washington, D.C. Throughout the meeting, Corindus will highlight occupational safety and robotic precision during percutaneous coronary intervention (PCI) procedures, including radiation exposure reduction by robotic-assisted PCI.
Sessions highlighting the CorPath System:
The Corindus CorPath System is the first FDA-approved medical device to bring robotic precision and accuracy to help optimize clinical outcomes during coronary angioplasties. Additionally, the CorPath System reduces radiation exposure for the interventional cardiologist.
“Radiation poses a risk to the health and safety of interventional cardiologists today; however, use of the CorPath System has proven to reduce radiation exposure while providing robotic precision during PCI,” said David Handler, President and CEO of Corindus Vascular Robotics. “Radiation exposure as an occupational hazard among interventional cardiologists is becoming a growing concern that must be addressed, and Corindus is dedicated to advocating for the safety of these physicians and their patients. TCT provides an ideal forum for us to bring these issues to the forefront.”
Recent studies and published articles pointing to the risks associated with traditional PCI procedures include:
For more information on the symposium, “Robotic PCI: Precision and Protection from Occupational Hazards,” click here.
TCT Meeting attendees can register here to use the CorPath System in a simulator environment at the Corindus Vascular Robotics Booth #1342.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements:
